Medicines boss: Costly new cancer drugs not working
Just one in 20 new cancer drugs assessed for the Irish market since the beginning of 2016 were considered value for money, according to a new assessment by the NCPE
Most new cancer drugs are not worth the money being sought by pharmaceutical companies, the head of the state’s medicines watchdog has said in a stark assessment.
Professor Michael Barry, who heads up the National Centre for Pharmacoeconomics (NCPE), said the state was funding cancer drugs that cost anywhere between €50,000 and €100,000 per patient per year that “very often only prolong life by a few months – if even [that]”.
Just one ...
